Intriguingly, it has been demonstrated that epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) mutations that normally drive the therapeutic decisions in the management of LC patients are either less frequent in IPF-LC adenocarcinoma patients compared with LC adenocarcinoma patients or have not been studied, respectively [135]. The gene discussed is EGFR; the disease is adenocarcinoma.